Oncology

Papers
(The H4-Index of Oncology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Metastatic Prostate Cancer: Treatment Options70
Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma38
The Emergence of Artificial Intelligence within Radiation Oncology Treatment Planning31
A Review of Applications of Machine Learning in Mammography and Future Challenges26
Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma22
Non-Muscle Invasive Bladder Cancer with Variant Histology: Biological Features and Clinical Implications20
Cholangiocarcinoma Evaluation via Imaging and Artificial Intelligence17
BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma17
The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study17
Current Status and Quality of Machine Learning-Based Radiomics Studies for Glioma Grading: A Systematic Review17
Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors16
The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials15
Diagnostic Challenges of Medullary Thyroid Carcinoma15
Inflammatory Biomarkers as Promising Predictors of Prognosis in Cervical Cancer Patients15
Localized and Locally Advanced Prostate Cancer: Treatment Options14
Systemic Effects of Radiation Therapy-Induced Abscopal Responses in Patients with Advanced Lung Cancer14
Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma14
Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma14
0.084113121032715